Impact of Perioperative Bridging Therapy on Thrombotic and Bleeding Events Among Patients Undergoing Major Surgical Procedures
World Journal of Surgery · 2026
DOI: 10.1002/wjs.70215 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgery, 2026. Verfasst von Zayed Rashid und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Conemaugh Memorial Medical Center, Johnstown, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anticoagulants, Heparin, Low-Molecular-Weight, Perioperative Care, Thrombosis. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
Background
The use of perioperative bridging therapy remains a topic of debate due to its associated risks and benefits. Therefore, we sought to characterize the association of bridging therapy with thrombotic and bleeding events following a major surgical procedure.
Method
Patients who underwent surgical procedures between 2022 and 2024 were identified using Epic Cosmos database in this retrospective cohort study. Bridging therapy (BT) was defined by the receipt of low molecular weight heparin (LMWH) or unfractionated heparin within 5 days before surgery. Thrombotic and bleeding events within 30‐day following surgery were examined using entropy balancing (EB) and multivariable regression models.
Results
Among 36,699 patients (i.e., pneumonectomy: n = 5829, 15.9%, esophagectomy: n = 434, 1.2%, gastrectomy: 4574, 12.5%, pancreatectomy: n = 983, 2.7%, hepatectomy: n = 946, 2.6%, biliary resection: n = 7034, 19.2%, and colectomy: n = 16,899, 46.0%), most were male ( n = 19,418, 52.9%) with a mean age of 70 years (standard deviation: ± 13 years); 59.9% ( n = 21,831) of patients received bridging therapy before a major surgical procedure. Following surgery, 4.6% (1673) of patients had VTE, 1.7% ( n = 625) had CVA, and 12.3% ( n = 4532) had bleeding. Following EB weighting, patients who received bridging therapy had 16% lower odds of CVA (OR: 0.84, 95% CI 0.71–0.99) and 12% lower odds of VTE (OR: 0.88, 95% CI 0.80–0.97); there was no difference in incidence of major bleeding events (OR: 0.97, 95% CI 0.91–1.03).
Conclusion
Roughly one in two patients undergoing surgery received bridging therapy. Bridging therapy was associated with reduced risk of thrombotic complications and no increase in major bleeding events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Conemaugh Memorial Medical Center, Johnstown, Pennsylvania, USA.
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, Ohio, USA.
ORCID-Profile: Timothy M Pawlik
Zitieren
APA
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Shah, A., Zindani, S., Sarfraz, A., & Pawlik, T. M. (2026). Impact of Perioperative Bridging Therapy on Thrombotic and Bleeding Events Among Patients Undergoing Major Surgical Procedures. World Journal of Surgery. https://doi.org/10.1002/wjs.70215
Vancouver
Rashid Z, Woldesenbet S, Khalil M, Altaf A, Shah A, Zindani S, et al. Impact of Perioperative Bridging Therapy on Thrombotic and Bleeding Events Among Patients Undergoing Major Surgical Procedures. World Journal of Surgery. 2026. doi:10.1002/wjs.70215
BibTeX
@article{Rashid2026,
author = {Rashid, Zayed and Woldesenbet, Selamawit and Khalil, Mujtaba and Altaf, Abdullah and Shah, Anand and Zindani, Shahzaib and Sarfraz, Azza and Pawlik, Timothy M},
title = {Impact of Perioperative Bridging Therapy on Thrombotic and Bleeding Events Among Patients Undergoing Major Surgical Procedures},
journal = {World Journal of Surgery},
year = {2026},
doi = {10.1002/wjs.70215}
}
EUVIMED